Flutemetamol, an investigational positron emission tomography imaging agent, to support Merck's development of MK-8931, an oral, beta-amyloid precursor protein site cleaving enzyme inhibitor in development for Alzheimer's disease...Shire plc, of Dublin, Ireland, reported a positive outcome from the European Decentralised Procedure for Elvanse (to be known as Tyvense in Ireland), indicated as part of a comprehensive treatment program for attention-deficit hyperactivity disorder in children, ages 6

reported a method to manufacture seven distinct types of cartilage, bone and tendon cells from human embryonic stem cells in a paper published online in Regenerative Medicine...Gentium expects to receive an opinion from the agency regarding the approval of defibrotide during the first quarter of 2013...Paladin expects to launch Silenor in the middle of 2013

BIT225 is designed to specifically target HIV in reservoir cells to stop the ongoing cycle of infection in the body...Those and other data were presented at the American Society of Hematology meeting in Atlanta

The HexaBody platform will be used to create differentiated antibody therapeutics, to improve the efficacy of existing antibody products and potentially to repurpose drug candidates that were unsuccessful in previous clinical trials due to lack of potency...The technology has the potential to enhance antibody therapeutics for a broad range of applications in cancer and infectious diseases, according to the company

Ltd., of Seoul, South Korea, agreed to establish a venture in South Korea under which Teva will contribute its global resources, with responsibilities for manufacturing and supplying a wide range of medicines, while Handok will handle sales and marketing, distribution and regulatory affiars...and Canada to Probuphine, a subdermal implant and a long-acting product designed to deliver six months of buprenorphine hydrochloride following a single treatment

The amount is in addition to approximately $500 million remaining under the previously announced $10 billion share repurchase program...Genzyme plans to request a re-examination of the CHMP Opinion...Raxibacumab also is approved to prevent inhalational anthrax when alternative therapies are not available or not appropriate

The cornerstone of the initiative is the MMRF CoMMpass study, which is designed to follow 1,000 newly diagnosed multiple myeloma patients over five years to understand the molecular changes underpinning the progress of the disease...Vanda said it intends to appeal the opinion and request a re-examination of the CHMP decision

The company expects to receive about $725,200 after sales commission and other expenses...Under the 2010 collaboration, Genmab is tasked with creating human antibodies to three central nervous system targets identified by Lundbeck

The alliance will involve researchers from both organizations working together to investigate new ways of treating neurological diseases such as Alzheimer's, Parkinson's and other related disorders...The goal will be to identify and validate drug targets, develop new therapeutics and evaluate them in proof-of-concept trials

The transaction is expected to close in early 2013...The single-tablet, combination regimen is designed to provide convenience for diabetes patients...marketing rights to canagliflozin except for parts of Asia

According to the approved product labeling, the treatment may now be used as a first-line agent or concomitantly with other topical ophthalmic drug products to lower IOP

Shares of Somaxon (NASDAQ:SOMX) soared on the buyout news, gaining 80.3 percent, or $1.18, to close Tuesday at $2.65. (See BioWorld Today, March 19, 2010, July 16, 2010, Aug. 26, 2010, and June 9, 2011...to identify and nominate highly differentiated backup and follow-on IAP inhibitors...Ltd., pursuant to the existing license, commercialization and supply agreement between Sucampo Pharma Ltd., SPI's subsidiary, and Abbott

Eisai has a pending new drug application for Aciphex delayed-release sprinkle capsules 5 mg and 10 mg for the proposed indication of gastroesophageal reflux disease (GERD), maintenance of healing of GERD and improvement of symptoms of GERD in children, ages 1 to 11

Distribution of Prothena ordinary shares in the demerger is conditioned upon, among other conditions to the demerger, a registration statement filed with the SEC, having been declared effective by the SEC and the affirmative vote of the Elan shareholders...Galderma will continue to supply Restylane and Perlane to Valeant under the same terms and conditions that the products are supplied to Medicis, while Valeant will make undisclosed up-front and royalty payments to Galderma on sales of Sculptra...To

The decision to delist stemmed from the firm's inability to maintain the continuous listing requirements...Payments to Isis could total $200 million, including license fees and regulatory milestones per program, plus additional double-digit royalties...Geron agreed to assign to TA Sciences Inc., of New York, those patents previously licensed to Asia Biotech, including intellectual property relating to telomerase activation technology

GlaxoSmithKline plc, of London, and the Fred Hutchinson Cancer Research Center entered a partnership to develop therapeutics to treat an inherited form of muscular dystrophy...The goal of the agreement is to develop a small-molecule-based medicine to potentially reverse facioscapulohumeral muscular dystrophy by inhibiting the activity of a protein that is incorrectly expressed by the DUX4 gene in people with the disease

The company plans to direct its cash and other resources primarily to enable the achievement of important near-term milestones for its BCX4161 HAE, BCX4430 broad-spectrum antiviral and BCX5191 hepatitis C programs

Reddy's Laboratories Ltd., of Hyderabad, India, acquired exclusive marketing and sales rights to Pamorelin LA (triptorelin) Depot, by Debiopharm Group, of Lausanne, Switzerland, in India for locally advanced or metastatic, hormone-dependent prostate cancer

Janssen Biotech Inc., of Horsham, Pa., and Janssen Biologics B.V., of Leiden, Netherlands, both part of Johnson & Johnson, submitted a supplemental biologics license application (sBLA) to the FDA and a Type II Variation to the European Medicines Agency (EMA) requesting approval of Stelara (ustekinumab) to treat adult patients with active psoriatic arthritis...The FDA gave guidance and permission to Lipocine Inc., of Salt Lake City, for its Phase III study of oral testosterone replacement therapy